A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink. CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells. … Read More
News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner. This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one… Read More
Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours. Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment. Dispatch’s Flare platform has been engineered to overcome these. Read More
OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma. The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More
The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been removed. The Food and Drug Administration (FDA) has determined that a REMS is no longer necessary to ensure that the benefits of these CAR T cell immunotherapies… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there… Read More
News round-up for 16-20 June by DDW Senior Digital Content Editor Diana Spencer. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers. Read More
Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust. Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy. Results… Read More
Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac. With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies. The company’s oncology strategy focuses on two pan-tumour programmes, mRNA-based cancer… Read More
A new paper has presented the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections. The study in The Journal of Immunology presents proof-of-concept data for CTX-09, an early molecule built on Centauri Therapeutics’ Alphamer platform. In… Read More
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting. This is RBL's first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for its lead cancer… Read More
Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing. The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other… Read More
Researchers at The University of Queensland (UQ) have launched the first clinical trial of a potentially revolutionary immunotherapy drug to treat type 1 diabetes. Professor Ranjeny Thomas from UQ’s Frazer Institute has led the development of a targeted immunotherapy drug, ASITI-201, which has been designed to rebalance… Read More
NHS England has become the first national health service in Europe to offer Bristol Myers Squibb’s injectable cancer immunotherapy nivolumab (Opdivo). Nivolumab is a monoclonal antibody that binds to PD-1 (programmed death-1) on T-cells. The jab can be used to treat 15 cancer types, including… Read More
DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company's cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More
Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC). The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More
